To qualify, patients must also have a body mass index (BMI) of 25 kg/ or higher or be unable to undergo basal insulin therapy
one tracks real spending behaviour through transaction data, where patients spend, how often, and how digital is changing it one focuses on patient expectations and experience, what drives trust, loyalty, value, and drop off one looks at sector operations, especially pharmacy, resilience, service expansion, and what is changing on the ground That shifts the real question from, how do we get more patients, to, how do we grow from the patients we already serve
This expansion of indications could significantly enhance the drugs utility, providing a comprehensive solution for managing a range of metabolic health issues
Some patients approach GLP-1 therapy as a temporary intervention, aiming to achieve a target weight before discontinuing treatment
& Ismail, N